
  
    
      
        Background_NNP
        Sickle_NNP cell_NN anemia_NN (_( Hb_NNP SS_NNP )_) results_NNS from_IN homozygosity_NN for_IN
        a_DT A_DT →_NN T_NN substitution_NN at_IN codon_NN 6_CD of_IN the_DT β-globin_JJ gene_NN
        (_( GAG_NNP →_NN GTG_NNP )_) leading_VBG to_TO a_DT glutamic_JJ acid_NN to_TO valine_NN (_( Glu_NNP →_NN Val_NNP )_)
        substitution_NN in_IN the_DT β_NN globin_NN chain_NN of_IN human_JJ adult_NN
        hemoglobin_NN ._. Despite_IN this_DT common_JJ genetic_JJ background_NN ,_,
        phenotypic_JJ expression_NN of_IN sickle_NN cell_NN disease_NN is_VBZ widely_RB
        variable_JJ ,_, ranging_VBG from_IN a_DT mild_JJ ,_, asymptomatic_JJ course_NN with_IN
        survival_NN into_IN the_DT sixth_JJ or_CC seventh_JJ decade_NN to_TO a_DT very_RB severe_JJ
        course_NN with_IN multi-organ_JJ damage_NN and_CC early_JJ mortality_NN [_NN 1_CD ]_NN ._.
        Some_DT of_IN the_DT genetic_JJ factors_NNS contributing_VBG to_TO this_DT phenotypic_JJ
        diversity_NN (_( particularly_RB those_DT linked_VBN to_TO the_DT globin_NN genes_NNS ,_,
        i_NNP ._. e_SYM ._. α-thalassemia_JJ and_CC β-globin_JJ gene_NN cluster_NN haplotypes_NNS )_)
        have_VBP been_VBN well_RB recognized_VBN [_NN 2_CD ]_NN ._.
        Stroke_NNP is_VBZ a_DT devastating_JJ complication_NN of_IN sickle_NN cell_NN
        disease_NN ,_, which_WDT occurs_VBZ in_IN 11_CD %_NN of_IN the_DT patients_NNS by_IN 20_CD years_NNS of_IN
        age_NN as_IN shown_VBN by_IN the_DT multi-center_JJ Cooperative_NNP Study_NNP of_IN
        Sickle_NNP Cell_NNP Disease_NNP (_( CSSCD_NNP )_) [_NN 3_CD 4_CD ]_NN ._. In_IN sickle_NN cell_NN
        patients_NNS <_NN 20_CD years_NNS of_IN age_NN ,_, stroke_NN is_VBZ predominantly_RB
        ischemic_JJ and_CC results_NNS from_IN the_DT involvement_NN of_IN medium_NN sized_VBD
        to_TO large_JJ intracranial_NN arteries_NNS ._. Ischemic_NNP stroke_NN in_IN the_DT
        general_JJ population_NN is_VBZ considered_VBN a_DT multi-genic_JJ disorder_NN [_NN 5_CD
        6_CD ]_NN ._. In_IN many_JJ cases_NNS it_PRP results_VBZ from_IN multiple_JJ gene-gene_JJ and_CC
        gene-environment_JJ interactions_NNS ._. In_IN the_DT case_NN of_IN sickle_NN cell_NN
        disease_NN ,_, only_RB a_DT few_JJ genetic_JJ factors_NNS are_VBP known_VBN to_TO influence_VB
        the_DT stroke_NN risk_NN [_NN 7_CD ]_NN ._. For_IN example_NN ,_, α-thalassemia_JJ is_VBZ the_DT
        only_RB well_RB characterized_VBN protective_JJ genetic_JJ factor_NN [_NN 7_CD ]_NN ._.
        Thus_RB ,_, genetic_JJ factors_NNS that_WDT lead_VBP to_TO the_DT development_NN of_IN
        cerebrovascular_NN disease_NN and_CC stroke_NN in_IN children_NNS with_IN Hb_NNP SS_NNP
        are_VBP not_RB well_RB understood_VBN ._.
        Studies_NNS conducted_VBD at_IN the_DT Medical_NNP College_NNP of_IN Georgia_NNP
        (_( MCG_NNP )_) in_IN the_DT mid-_NN 1980_CD 's_POS have_VBP shown_VBN that_DT transcranial_NN
        doppler_NN (_( TCD_NNP )_) can_MD identify_VB children_NNS at_IN high_JJ risk_NN for_IN stroke_NN
        by_IN detecting_VBG high_JJ flow_NN rate_NN in_IN major_JJ intracranial_NN arteries_NNS
        [_NN 8_CD 9_CD ]_NN ._. Children_NNP with_IN flow_NN velocities_NNS of_IN 200_CD cm_NN /_NN sec_NN or_CC
        higher_JJR in_IN middle_JJ cerebral_JJ or_CC internal_JJ carotid_NN arteries_NNS
        (_( normal_JJ =_SYM 140_CD -_: 170_CD cm_NN /_NN sec_NN for_IN sickle_NN cell_NN children_NNS )_) had_VBD a_DT
        stroke_NN risk_NN of_IN 10_CD -_: 15_CD %_NN per_IN year_NN ,_, which_WDT represents_VBZ a_DT 20_CD -_: fold_VB
        increase_NN over_IN that_DT for_IN unselected_JJ children_NNS with_IN sickle_NN cell_NN
        disease_NN ._. These_DT observations_NNS then_RB led_VBN to_TO the_DT multicenter_NN
        STOP_NNP (_( Stroke_NNP Prevention_NNP Trial_NNP in_IN Sickle_NNP Cell_NNP Anemia_NNP )_) study_NN
        in_IN which_WDT sickle_NN cell_NN children_NNS age_VBP 2_CD -_: 16_CD years_NNS ,_, from_IN 14_CD
        centers_NNS in_IN the_DT U_NNP ._. S_NNP ._. and_CC Canada_NNP ,_, were_VBD screened_VBD by_IN TCD_NNP [_NN 10_CD ]_NN
        ._. One_CD hundred_CD thirty_CD patients_NNS with_IN flow_NN velocities_NNS of_IN
        >_NN 200_CD cm_NN /_NN sec_NN were_VBD randomized_JJ to_TO observation_NN or_CC to_TO receive_VB
        periodic_JJ blood_NN transfusions_NNS to_TO reduce_VB %_NN Hb_NNP S_NNP to_TO <_NN 30_CD ._. The_DT
        study_NN was_VBD stopped_VBN early_RB by_IN the_DT Data_NNP and_CC Safety_NNP Monitoring_NN
        Board_NNP due_JJ to_TO the_DT finding_NN of_IN a_DT significant_JJ reduction_NN in_IN the_DT
        number_NN of_IN strokes_NNS (_( 90_CD %_NN reduction_NN ,_, p_NN <_NN ._. 001_CD )_) in_IN the_DT
        transfusion_NN arm_NN (_( 11_CD strokes_NNS in_IN the_DT observation_NN arm_NN vs_NNS ._. one_CD
        in_IN the_DT transfusion_NN arm_NN )_) [_NN 11_CD ]_NN ._. Thus_RB ,_, the_DT STOP_NNP study_NN
        established_VBN that_DT transfusion_NN was_VBD an_DT effective_JJ means_NNS of_IN
        primary_JJ stroke_NN prevention_NN in_IN children_NNS with_IN sickle_NN cell_NN
        disease_NN at_IN risk_NN for_IN stroke_NN as_IN determined_VBN by_IN TCD_NNP ._. The_DT
        recently_RB funded_VBN STOP-II_NNP study_NN ,_, to_TO be_VB conducted_VBN in_IN 24_CD
        centers_NNS ,_, will_MD investigate_VB the_DT duration_NN of_IN stroke_NN risk_NN and_CC
        the_DT feasibility_NN of_IN discontinuing_VBG transfusion_NN after_IN 30_CD
        months_NNS in_IN patients_NNS whose_WP$ TCD_NNP velocities_NNS have_VBP normalized_JJ
        after_IN transfusion_NN ._.
        Data_NNS from_IN the_DT STOP_NNP study_NN showed_VBD that_DT ~_NN 10_CD %_NN of_IN patients_NNS
        with_IN Hb_NNP SS_NNP between_IN the_DT ages_NNS of_IN 2_CD -_: 16_CD years_NNS are_VBP at_IN risk_NN for_IN
        stroke_NN as_IN determined_VBN by_IN Transcranial_NNP Doppler_NNP (_( TCD_NNP )_)
        velocities_NNS of_IN 200_CD cm_NN /_NN sec_NN or_CC greater_JJR [_NN 11_CD ]_NN ._. TCD_NNP velocity_NN
        elevation_NN can_MD be_VB due_JJ to_TO two_CD factors_NNS :_: reduction_NN of_IN arterial_NN
        diameter_NN due_JJ to_TO stenosis_NNS and_CC /_NN or_CC increased_VBN volume_NN flow_NN
        through_IN the_DT artery_NN ._. In_IN the_DT case_NN of_IN sickle_NN cell_NN disease_NN ,_,
        both_DT factors_NNS are_VBP often_RB present_JJ ._. Velocity_NNP elevation_NN
        corresponding_JJ to_TO increased_VB cerebral_JJ blood_NN flow_NN in_IN all_DT
        patients_NNS with_IN anemia_NN has_VBZ been_VBN noted_VBN ,_, with_IN an_DT approximate_JJ
        linear_JJ increase_NN in_IN velocity_NN for_IN decrease_NN in_IN Hb_NNP or_CC HCT_NNP [_NN 12_CD
        ]_NN ._. There_EX are_VBP also_RB data_NNS to_TO suggest_VB that_IN patients_NNS with_IN Hb_NNP SS_NNP
        have_VBP higher_JJR flow_NN velocities_NNS than_IN those_DT with_IN normal_JJ Hb_NNP A_DT at_IN
        comparable_JJ levels_NNS of_IN anemia_NN ,_, suggesting_VBG the_DT amount_NN and_CC
        composition_NN of_IN the_DT Hb_NNP are_VBP both_DT involved_VBN in_IN the_DT velocity_NN
        elevation_NN of_IN sickle_NN cell_NN disease_NN [_NN 13_CD ]_NN ._.
        While_IN some_DT of_IN the_DT risk_NN factors_NNS leading_VBG to_TO the_DT
        development_NN of_IN cerebral_JJ vasculopathy_NN and_CC stroke_NN in_IN sickle_NN
        cell_NN disease_NN (_( low_JJ hematocrit_NN ,_, elevated_VBD white_JJ blood_NN cell_NN
        count_NN ,_, normal_JJ complement_VB of_IN α-globin_JJ genes_NNS )_) have_VBP been_VBN
        identified_VBN in_IN previous_JJ studies_NNS (_( CSSCD_NNP ,_, MCG_NNP cohort_NN ,_, and_CC
        STOP_NNP )_) ,_, many_JJ remain_VB unknown_JJ ._. The_DT observation_NN has_VBZ been_VBN made_VBN
        that_IN strokes_NNS in_IN sickle_NN cell_NN disease_NN are_VBP clustered_VBN in_IN
        families_NNS ,_, but_CC no_DT clear_JJ epidemiological_JJ confirmation_NN of_IN this_DT
        has_VBZ been_VBN published_VBN ._. In_IN terms_NNS of_IN TCD_NNP velocities_NNS ,_, it_PRP was_VBD
        noted_VBN in_IN the_DT STOP_NNP study_NN that_IN sibling_VBG pairs_NNS were_VBD common_JJ
        among_IN abnormals_NNS (_( i_NNP ._. e_SYM ._. ,_, TCD_NNP >_NN 200_CD cm_NN /_NN sec_NN )_) and_CC there_EX were_VBD
        5_CD pairs_NNS among_IN 130_CD randomized_JJ patients_NNS suggesting_VBG that_IN other_JJ
        genetic_JJ factors_NNS may_MD in_IN part_VB determine_VB propensity_NN for_IN stroke_NN
        (_( RJ_NNP Adams_NNP ,_, unpublished_JJ observations_NNS )_) ._.
        Various_JJ mechanisms_NNS have_VBP been_VBN proposed_VBN to_TO account_VB for_IN the_DT
        "_'' hypercoagulable_JJ state_NN "_'' observed_VBD in_IN patients_NNS with_IN sickle_NN
        cell_NN disease_NN ._. These_DT include_VBP increased_VBN platelet_NN activation_NN ,_,
        increased_VBN thrombin_NN generation_NN ,_, and_CC more_RBR recently_RB ,_, elevated_VBD
        levels_NNS of_IN circulating_VBG tissue_NN factor_NN [_NN 14_CD ]_NN ._. Over_IN the_DT past_JJ
        decade_NN ,_, mutations_NNS in_IN a_DT number_NN of_IN genes_NNS have_VBP been_VBN identified_VBN
        as_IN the_DT cause_NN of_IN thrombophilia_NN in_IN a_DT large_JJ number_NN of_IN patients_NNS
        from_IN different_JJ populations_NNS around_IN the_DT globe_NN ._. The_DT molecular_JJ
        basis_NN of_IN inherited_VBN thrombophilia_NN now_RB includes_VBZ mutations_NNS in_IN
        the_DT genes_NNS for_IN Factor_NN V_NNP ,_, prothrombin_NN ,_,
        methylenetetrahydrofolate_NN reductase_NN (_( MTHFR_NNP )_) and_CC several_JJ
        others_NNS [_NN 15_CD ]_NN ,_, in_IN addition_NN to_TO those_DT encoding_VBG proteins_NNS such_JJ
        as_IN antithrombin_NN ,_, protein_NN C_NNP ,_, and_CC protein_NN S_NNP whose_WP$ role_NN in_IN the_DT
        homeostasis_NNS between_IN procoagulant_NN and_CC anticoagulant_NN
        activities_NNS in_IN the_DT circulation_NN is_VBZ well_RB established_VBN ._. Unlike_IN
        rare_JJ mutations_NNS involving_VBG antithrombin_NN ,_, protein_NN C_NNP and_CC S_NNP ,_,
        which_WDT are_VBP clearly_RB associated_VBN with_IN a_DT hypercoagulable_JJ
        phenotype_NN ,_, mutations_NNS we_PRP propose_VBP to_TO study_VB appear_VBP to_TO have_VB two_CD
        distinct_JJ features_NNS :_: i_NNP )_) they_PRP occur_VBP with_IN a_DT significantly_RB
        higher_JJR frequency_NN in_IN many_JJ populations_NNS ,_, and_CC ii_NN )_) they_PRP seem_VBP to_TO
        contribute_VB to_TO a_DT thrombophilic_JJ state_NN in_IN the_DT presence_NN of_IN
        additional_JJ acquired_VBN (_( environmental_JJ /_NN nutritional_JJ )_) or_CC
        inherited_VBN (_( interaction_NN with_IN other_JJ genes_NNS )_) factors_NNS ._.
        It_PRP is_VBZ likely_JJ that_IN the_DT co-inheritance_JJ of_IN one_CD or_CC more_JJR of_IN
        these_DT mutations_NNS in_IN sickle_NN cell_NN disease_NN would_MD tip_VB the_DT
        balance_NN toward_IN a_DT hypercoagulable_JJ state_NN and_CC act_NN as_IN an_DT
        additional_JJ risk_NN factor_NN for_IN the_DT development_NN of_IN
        cerebrovascular_NN disease_NN ._. Additionally_RB ,_, the_DT effect_NN of_IN the_DT
        thermolabile_NN MTHFR_NNP mutation_NN (_( 677_CD C_NNP →_NN T_NN )_) on_IN plasma_NN
        homocysteine_NN levels_NNS in_IN heterozygotes_NNS has_VBZ been_VBN shown_VBN to_TO
        depend_VB upon_IN the_DT availability_NN of_IN folate_NN ,_, with_IN higher_JJR levels_NNS
        seen_VBN in_IN folate_NN deficient_NN individuals_NNS ._. It_PRP is_VBZ possible_JJ that_WDT
        increased_VBD folate_NN requirements_NNS due_JJ to_TO chronic_JJ hemolysis_NNS in_IN
        sickle_NN cell_NN disease_NN would_MD lead_VB to_TO a_DT relative_JJ deficiency_NN
        state_NN ,_, which_WDT ,_, in_IN the_DT presence_NN of_IN MTHFR_NNP mutation_NN ,_, would_MD
        result_VB in_IN higher_JJR homocysteine_NN levels_NNS as_IN an_DT additional_JJ risk_NN
        factor_NN for_IN vasculopathy_NN ._.
        Thus_RB ,_, we_PRP propose_VBP to_TO study_VB polymorphisms_NNS in_IN genes_NNS
        involved_VBN in_IN a_DT number_NN of_IN systems_NNS and_CC pathways_NNS related_VBN to_TO
        stroke_NN risk_NN [_NN 5_CD ]_NN :_: genes_NNS associated_VBN with_IN coagulation_NN
        factors_NNS and_CC thrombophilia_NN (_( Factor_NN V_NNP ,_, Prothrombin_NNP ,_,
        Fibrinogen_NNP ,_, Factor_NN VII_NNP ,_, Factor_NN XIII_NNP ,_, PAI-_NNP 1_CD ,_, Thrombomodulin_NNP
        [_NN TM_NNP ]_NN ,_, and_CC MTHFR_NNP )_) ,_, as_RB well_RB as_IN polymorphisms_NNS in_IN genes_NNS that_WDT
        are_VBP involved_VBN in_IN vascular_NN reactivity_NN (_( ACE_NNP )_) ,_, platelet_NN
        activation_NN /_NN function_NN (_( GpIIb_NNP /_NN IIIa_NNP ,_, GpIb_NNP IX-V_NNP ,_, and_CC GpIa_NNP /_NN IIa_NNP )_) ,_,
        endothelial_NN cell_NN function_NN (_( MTHFR_NNP ,_, TM_NNP ,_, VCAM-_NNP 1_CD ,_, E-S_NNP electin_NN ,_,
        L-S_NNP electin_NN ,_, P-S_NNP electin_NN ,_, and_CC ICAM-_NNP 1_LS )_) ,_, inflammation_NN (_( TNFα_NNP )_) ,_,
        lipid_NN metabolism_NN (_( Apo_NNP A_DT 1_CD and_CC Apo_NNP E_NNP )_) ,_, and_CC cell_NN adhesion_NN
        (_( VCAM-_NNP 1_CD ,_, E-S_NNP electin_NN ,_, L-S_NNP electin_NN ,_, P-S_NNP electin_NN ,_, and_CC ICAM-_NNP 1_LS )_) ._.
        These_DT candidate_NN genes_NNS will_MD make_VB it_PRP possible_JJ to_TO study_VB not_RB
        only_RB polymorphisms_NNS associated_VBN with_IN a_DT hypercoagulable_JJ state_NN ,_,
        but_CC also_RB to_TO study_VB the_DT genes_NNS involved_VBN in_IN pathways_NNS that_WDT may_MD
        lead_VB to_TO the_DT development_NN of_IN vasculopathy_NN (_( genes_NNS involved_VBN in_IN
        endothelial_NN cell_NN function_NN ,_, inflammation_NN ,_, and_CC adhesion_NN ,_,
        platelet_NN activation_NN and_CC responsiveness_NNS )_) ._. Thus_RB ,_, this_DT will_MD
        provide_VB the_DT rationale_NN for_IN studying_VBG potential_JJ genetic_JJ risk_NN
        factors_NNS that_WDT may_MD contribute_VB to_TO the_DT pathogenesis_NNS of_IN an_DT
        "_'' intermediate_JJ phenotype_NN ,_, "_'' such_JJ as_IN vasculopathy_NN [_NN 5_CD ]_NN rather_RB
        than_IN a_DT thrombotic_JJ endpoint_NN (_( i_NNP ._. e_SYM ._. stroke_NN )_) ._. TCD_NNP remains_VBZ the_DT
        only_RB proven_VBN indicator_NN of_IN cerebrovascular_NN disease_NN and_CC stroke_NN
        risk_NN in_IN Hb_NNP SS_NNP ._. Therefore_RB ,_, a_DT large_JJ case-control_JJ association_NN
        study_NN of_IN the_DT role_NN of_IN genes_NNS in_IN the_DT development_NN of_IN
        cerebrovascular_NN disease_NN and_CC stroke_NN risk_NN based_VBN upon_IN TCD_NNP ,_, is_VBZ
        likely_JJ to_TO provide_VB more_RBR accurate_JJ information_NN and_CC may_MD resolve_VB
        the_DT controversial_JJ results_NNS obtained_VBN in_IN smaller_JJR studies_NNS [_NN 5_CD ]_NN
        ._. Furthermore_RB ,_, an_DT attempt_NN will_MD be_VB made_VBN to_TO perform_VB a_DT subset_NN
        analysis_NN of_IN patients_NNS who_WP go_VBP on_IN to_TO have_VB an_DT ischemic_JJ stroke_NN
        during_IN the_DT study_NN period_NN in_IN terms_NNS of_IN the_DT associations_NNS with_IN
        genetic_JJ polymorphisms_NNS ._. As_IN of_IN the_DT termination_NN of_IN the_DT study_NN
        in_IN 2000_CD ,_, 18_CD of_IN the_DT 130_CD patients_NNS randomized_JJ in_IN STOP_NNP have_VBP
        been_VBN adjudicated_JJ to_TO have_VB a_DT stroke_NN ._.
        In_IN summary_NN ,_, we_PRP have_VBP designed_VBN a_DT case-control_JJ association_NN
        study_NN to_TO elucidate_NN the_DT role_NN of_IN genetic_JJ polymorphisms_NNS as_IN
        risk_NN factors_NNS for_IN cerebrovascular_NN disease_NN ,_, measured_VBN by_IN a_DT
        high_JJ TCD_NNP velocity_NN ,_, in_IN children_NNS with_IN Hb_NNP SS_NNP ._. The_DT study_NN will_MD
        consist_VB of_IN two_CD parts_NNS ,_, a_DT candidate_NN gene_NN study_NN and_CC a_DT
        genomewide_NN screen_NN and_CC will_MD be_VB performed_VBN in_IN 230_CD cases_NNS and_CC
        400_CD controls_NNS ._. Cases_NNS will_MD include_VB 130_CD patients_NNS randomized_JJ in_IN
        the_DT STOP_NNP study_NN (_( TCD_NNP ≥_NN 200_CD cm_NN /_NN s_VBZ )_) as_RB well_RB as_IN 100_CD patients_NNS
        found_VBD to_TO have_VB high_JJ TCD_NNP in_IN STOP_NNP II_NNP screening_NN ._. Four_CD hundred_CD
        sickle_NN cell_NN patients_NNS with_IN a_DT normal_JJ TCD_NNP velocity_NN (_( TCD_NNP <_NN
        170_CD cm_NN /_NN s_VBZ )_) will_MD be_VB used_VBN as_IN controls_NNS ._. The_DT candidate_NN gene_NN
        study_NN will_MD involve_VB the_DT analysis_NN of_IN 28_CD genetic_JJ polymorphisms_NNS
        in_IN 20_CD candidate_NN genes_NNS (_( see_VB Table_NNP 1_LS )_) ._. References_NNP for_IN the_DT
        polymorphisms_NNS listed_VBN in_IN Table_NNP 1_CD are_VBP provided_VBN in_IN the_DT
        additional_JJ file_NN 1_CD ._. The_DT genomewide_NN screen_NN for_IN a_DT large_JJ number_NN
        of_IN SNP_NNP markers_NNS may_MD uncover_VB the_DT association_NN of_IN novel_NN
        polymorphisms_NNS with_IN cerebrovascular_NN disease_NN and_CC stroke_NN in_IN
        sickle_NN cell_NN disease_NN ._. DNA_NN samples_NNS will_MD be_VB pooled_VBN in_IN the_DT 230_CD
        cases_NNS and_CC in_IN the_DT 400_CD controls_NNS and_CC these_DT pools_NNS will_MD be_VB
        genotyped_JJ for_IN a_DT large_JJ number_NN of_IN validated_JJ SNPs_NNP (_( we_PRP estimate_VBP
        to_TO need_NN at_IN least_JJS 100_CD ,_, 000_CD SNP_NNP markers_NNS )_) using_VBG high-throughput_JJ
        methods_NNS ._. Purpose_NNP of_IN this_DT paper_NN is_VBZ to_TO give_VB a_DT detailed_VBN
        description_NN of_IN the_DT design_NN of_IN this_DT study_NN ._.
        Additional_JJ File_NNP 1_CD
        The_DT 28_CD polymorphisms_NNS that_WDT will_MD be_VB studied_VBN are_VBP referenced_JJ
        in_IN an_DT attached_VBN document_NN :_: Design_NNP Paper_NNP ._. Reference_NNP list_NN for_IN
        polymorphisms_NNS ._. doc_NN ._.
        Click_NNP here_RB for_IN file_NN
      
      
        Research_NNP Design_NNP and_CC Methods_NNP
        
          Subjects_NNP
          African-_NNP American_JJ children_NNS who_WP are_VBP between_IN the_DT ages_NNS of_IN
          2_CD and_CC 16_CD years_NNS with_IN Hb_NNP SS_NNP or_CC Sβ_NNP 0_CD -_: thalassemia_NN from_IN
          participating_VBG STOP_NNP and_CC STOP_NNP II_NNP centers_NNS form_VBP the_DT subjects_NNS
          of_IN this_DT study_NN ._. The_DT STOP_NNP study_NN was_VBD conducted_VBN in_IN 14_CD centers_NNS
          in_IN North_JJ American_NNP (_( 13_CD US_NNP and_CC 1_CD Canadian_JJ )_) ._. STOP_NNP II_NNP is_VBZ
          being_VBG conducted_VBN in_IN 28_CD centers_NNS (_( 27_CD US_NNP and_CC 1_CD Canadian_JJ )_) ._.
          Banked_NNP DNA_NNP samples_NNS from_IN randomized_JJ STOP_NNP patients_NNS (_( n_NN =_SYM
          130_CD )_) stored_VBD in_IN the_DT STOP_NNP Core_NNP Laboratory_NNP will_MD be_VB utilized_JJ ._.
          An_DT additional_JJ 100_CD patients_NNS with_IN high_JJ TCD_NNP velocity_NN and_CC 400_CD
          control_NN patients_NNS with_IN normal_JJ TCD_NNP velocity_NN will_MD be_VB
          identified_VBN through_IN STOP-II_NNP screening_NN ._. With_IN an_DT abnormal_JJ
          TCD_NNP rate_NN of_IN 10_CD %_NN ,_, it_PRP is_VBZ expected_VBN that_IN at_IN least_JJS 1000_CD -_: 1400_CD
          new_JJ patients_NNS from_IN 24_CD participating_VBG Centers_NNPS will_MD need_VB to_TO
          be_VB screened_VBD as_IN part_NN of_IN the_DT STOP-II_NNP study_NN to_TO identify_VB 100_CD
          new_JJ patients_NNS with_IN TCD_NNP velocities_NNS >_NN 200_CD cm_NN /_NN sec_NN ._. DNA_NNP will_MD
          be_VB extracted_VBN from_IN the_DT 5_CD ml_NN blood_NN collected_VBN in_IN EDTA_NNP and_CC
          shipped_VBN to_TO the_DT Core_NNP Laboratory_NNP ,_, collected_VBN during_IN TCD_NNP
          screening_NN as_IN part_NN of_IN STOP-II_NNP ._.
          Cases_NNS and_CC controls_NNS will_MD be_VB matched_VBN for_IN age_NN ,_, sex_NN ,_, and_CC
          weight_NN ,_, which_WDT are_VBP the_DT most_RBS important_JJ covariates_NNS ._. The_DT
          effect_NN of_IN any_DT remaining_VBG differences_NNS in_IN additional_JJ
          confounding_VBG variables_NNS between_IN cases_NNS and_CC controls_NNS will_MD be_VB
          explored_JJ by_IN adjusting_VBG for_IN these_DT covariates_NNS in_IN the_DT
          analyses_NNS ,_, for_IN example_NN through_IN using_VBG conditional_JJ logistic_JJ
          regression_NN models_NNS ._.
        
        
          Human_NNP Biological_NNP Materials_NNPS
          To_TO ensure_VB confidentiality_NN and_CC protect_VB the_DT privacy_NN of_IN
          subjects_NNS they_PRP will_MD not_RB be_VB identified_VBN by_IN name_NN ,_, acrostics_NNS
          will_MD be_VB used_VBN ._. Authorized_NNP officials_NNS from_IN the_DT state_NN and_CC
          federal_JJ governments_NNS and_CC authorized_VBD representatives_NNS of_IN the_DT
          Medical_NNP College_NNP of_IN Georgia_NNP will_MD have_VB access_VB to_TO
          confidential_JJ data_NNS ,_, which_WDT will_MD identify_VB the_DT patients_NNS ._.
          Patients_NNS will_MD not_RB be_VB identified_VBN in_IN any_DT reports_NNS or_CC
          publications_NNS resulting_VBG from_IN this_DT study_NN ._. Banked_NNP STOP_NNP DNA_NNP
          samples_NNS were_VBD anonymized_JJ according_VBG to_TO a_DT plan_NN approved_VBN by_IN
          the_DT Institutional_NNP Review_NNP Boards_NNP of_IN the_DT Medical_NNP College_NNP of_IN
          Georgia_NNP and_CC the_DT New_NNP England_NNP Research_NNP Institute_NNP ._. Informed_NNP
          consent_NN was_VBD obtained_VBN for_IN subjects_NNS screened_VBD as_IN part_NN of_IN the_DT
          STOP_NNP II_NNP study_NN ._. In_IN accordance_NN with_IN the_DT National_NNP Bioethics_NNP
          Advisory_NNP Commission_NNP Recommendations_NNP [_NN 16_CD ]_NN subjects_NNS and_CC
          their_PRP$ physicians_NNS will_MD not_RB be_VB notified_VBN of_IN the_DT test_NN results_NNS
          unless_IN all_DT three_CD of_IN the_DT following_VBG conditions_NNS are_VBP met_VBN :_:
          1_LS )_) The_DT findings_NNS are_VBP scientifically_RB valid_JJ and_CC are_VBP
          confirmed_VBN
          2_LS )_) The_DT findings_NNS have_VBP significant_JJ implications_NNS for_IN the_DT
          subject_NN 's_POS health_NN concerns_NNS
          3_LS )_) A_DT course_NN of_IN action_NN to_TO treat_VB these_DT concerns_NNS is_VBZ
          readily_RB available_JJ
        
        
          SNP_NNP Genotyping_NNP
          DNA_NNP will_MD be_VB extracted_VBN from_IN peripheral_JJ blood_NN
          mononuclear_NN cells_NNS and_CC 5_CD μg_NN of_IN genomic_JJ DNA_NNP from_IN each_DT
          subject_NN will_MD be_VB used_VBN for_IN each_DT multiplex_NN SNP_NNP genotyping_VBG
          assay_NN (_( the_DT STOP_NNP DNA_NNP bank_NN has_VBZ 66_CD -_: 1740_CD μg_NN of_IN DNA_NNP from_IN
          randomized_JJ patients_NNS )_) ._. The_DT 28_CD polymorphisms_NNS in_IN 20_CD
          candidate_NN genes_NNS and_CC the_DT SNP_NNP markers_NNS in_IN the_DT genomewide_NN
          screen_NN will_MD be_VB genotyped_JJ by_IN high-throughput_JJ SNP_NNP screening_NN
          using_VBG the_DT MassARRAY_NNP ™_NN System_NNP (_( Sequenom_NNP Inc_NNP ._. ,_, San_NNP Diego_NNP ,_,
          CA_NNP )_) ._. The_DT principles_NNS of_IN this_DT method_NN are_VBP detailed_JJ in_IN
          references_NNS [_NN 17_CD ]_NN and_CC [_NN 18_CD ]_NN ._. Briefly_NNP ,_, approximately_RB 300_CD
          bp_NN fragments_NNS of_IN each_DT candidate_NN gene_NN ,_, with_IN the_DT SNP_NNP site_NN in_IN
          the_DT middle_NN ,_, will_MD be_VB amplified_VBN by_IN automated_VBN PCR_NNP procedure_NN ._.
          Multiplexing_NNP of_IN the_DT PCR_NNP reactions_NNS will_MD be_VB used_VBN as_IN
          determined_VBN by_IN the_DT Sequenom_NNP software_NN ._. One_CD of_IN the_DT
          amplification_NN primers_NNS includes_VBZ a_DT 5_CD '_POS biotin_NN tag_NN ,_, which_WDT is_VBZ
          targeted_VBN in_IN a_DT streptavidin-magnetic_JJ bead_NN purification_NN
          step_NN to_TO generate_VB a_DT single_JJ stranded_VBN template_NN for_IN the_DT
          primer_NN extension_NN reaction_NN ._. An_DT extension_NN primer_NN
          complimentary_JJ to_TO the_DT template_NN at_IN a_DT region_NN directly_RB
          adjacent_JJ to_TO the_DT SNP_NNP site_NN is_VBZ added_VBN to_TO the_DT single_JJ stranded_VBN
          template_NN ._. This_DT is_VBZ followed_VBN by_IN the_DT MassEXTEND_NNP ™_NN reaction_NN
          during_IN which_WDT the_DT primer_NN is_VBZ extended_VBN across_IN the_DT SNP_NNP site_NN
          by_IN using_VBG a_DT sequencing_VBG polymerase_NN reaction_NN ._. This_DT is_VBZ
          controlled_VBN by_IN a_DT mixture_NN of_IN dideoxy_NN and_CC deoxy_NN nucleotide_NN
          triphosphates_NNS ,_, the_DT ratio_NN of_IN which_WDT varies_VBZ depending_VBG upon_IN
          the_DT assay_NN design_NN protocol_NN obtained_VBN from_IN the_DT
          SpectroDESIGNER_NNP ™_NN software_NN (_( Sequenom_NNP )_) ._. The_DT primer_NN
          extension_NN products_NNS will_MD differ_VB depending_VBG upon_IN the_DT
          polymorphic_JJ base_NN present_JJ at_IN the_DT SNP_NNP site_NN ._. The_DT difference_NN
          in_IN molecular_JJ weight_NN between_IN these_DT products_NNS is_VBZ detectable_JJ
          by_IN mass_NN spectrometry_NN ._. Following_VBG the_DT extension_NN reaction_NN ,_,
          the_DT original_JJ sample_NN template_NN is_VBZ separated_VBN and_CC removed_VBN
          from_IN the_DT extended_VBN primers_NNS by_IN the_DT use_NN of_IN a_DT resin_NN ._. The_DT
          purified_JJ samples_NNS are_VBP then_RB transferred_VBN onto_IN a_DT SpectroCHIP_NNP ™_NN
          (_( from_IN either_DT a_DT 96_CD well_RB or_CC 384_CD well_RB plate_NN )_) with_IN the_DT
          SpectroJET_NNP ™_NN dispenser_NN ._. The_DT CHIP_NNP is_VBZ placed_VBN into_IN the_DT mass_NN
          spectrometer_NN ,_, which_WDT takes_VBZ advantage_NN of_IN the_DT MALDI-TOF_NNP
          (_( Matrix_NNP Assisted_NNP Laser_NNP Desorption_NNP /_NN Ionization_NNP
          Time-of-_NNP Flight_NNP )_) mass_NN spectrometry_NN ._. The_DT mixture_NN of_IN the_DT
          test_NN molecules_NNS (_( extension_NN products_NNS )_) with_IN the_DT organic_JJ
          matrix_NN produces_VBZ a_DT crystalline_JJ dispersion_NN ._. The_DT matrix_NN is_VBZ
          hit_VBN with_IN a_DT pulse_NN from_IN a_DT laser_NN beam_NN ._. The_DT sample_NN and_CC matrix_NN
          are_VBP vaporized_JJ and_CC the_DT primer_NN extension_NN products_NNS are_VBP
          expelled_VBN into_IN the_DT flight_NN tube_NN ._. As_IN the_DT primer_NN extension_NN
          products_NNS are_VBP negatively_RB charged_VBN when_WRB an_DT electrical_JJ field_NN
          pulse_NN is_VBZ subsequently_RB applied_VBN ,_, they_PRP are_VBP launched_VBN down_RP the_DT
          flight_NN tube_NN toward_IN the_DT detector_NN ._. The_DT time_NN between_IN
          application_NN of_IN the_DT electrical_JJ field_NN pulse_NN and_CC collision_NN
          of_IN the_DT primer_NN extension_NN products_NNS with_IN the_DT detector_NN is_VBZ
          known_VBN as_IN "_'' time-of-flight_JJ "_'' and_CC is_VBZ a_DT very_RB precise_JJ measure_NN
          of_IN the_DT product_NN 's_POS molecular_JJ weight_NN ._. The_DT SpectroTYPER_NNP ™_NN
          software_NN gathers_VBZ the_DT time-of-flight_JJ information_NN and_CC
          applies_VBZ algorithms_NNS to_TO provide_VB accurate_JJ ,_, automated_VBN
          genotype_NN calling_NN ._. This_DT method_NN is_VBZ fast_RB and_CC more_RBR accurate_JJ
          compared_VBN to_TO hybridization-based_JJ methods_NNS of_IN SNP_NNP detection_NN
          [_NN 17_CD 18_CD ]_NN ._. The_DT whole_JJ process_NN is_VBZ automated_VBN ._.
        
        
          Data_NNP Management_NNP
          Web-based_NNP data_NNS entry_NN will_MD be_VB used_VBN to_TO load_VB the_DT data_NNS
          from_IN this_DT study_NN into_IN the_DT password-protected_JJ STOP_NNP II_NNP
          database_NN at_IN the_DT New_NNP England_NNP Research_NNP Institutes_NNPS (_( NERI_NNP )_) ._. A_DT
          data_NNS entry_NN screen_NN specific_JJ to_TO this_DT study_NN will_MD be_VB
          developed_VBN for_IN this_DT purpose_NN ._. Adding_VBG the_DT data_NNS to_TO the_DT STOP_NNP
          II_NNP database_NN will_MD greatly_RB facilitate_VB linking_VBG the_DT
          genotyping_VBG data_NN to_TO other_JJ patient_NN characteristics_NNS (_( e_SYM ._. g_SYM ._.
          TCD_NNP status_NN )_) during_IN data_NNS analysis_NN ._. The_DT database_NN was_VBD
          developed_VBN using_VBG NERI_NNP 's_POS browser-based_JJ data_NNS management_NN
          system_NN ,_, ADEPT_NNP ,_, and_CC an_DT ORACLE_NNP relational_NN database_NN engine_NN ._.
          As_IN part_NN of_IN standard_JJ QC_NNP ,_, 10_CD %_NN of_IN the_DT records_NNS will_MD be_VB
          randomly_RB selected_VBN at_IN NERI_NNP for_IN double_JJ data_NNS entry_NN ._. Any_DT
          problems_NNS with_IN high_JJ error_NN rates_NNS will_MD be_VB brought_VBN to_TO the_DT
          attention_NN of_IN laboratory_NN personnel_NNS immediately_RB ._. If_IN
          necessary_JJ ,_, further_JJ records_NNS entered_VBN by_IN the_DT same_JJ individual_JJ
          will_MD also_RB be_VB reviewed_VBN ._.
        
        
          Statistical_NNP analysis_NN for_IN the_DT candidate_NN gene_NN
          study_NN
          As_IN a_DT first_JJ step_NN in_IN the_DT analysis_NN ,_, the_DT genotypic_JJ
          frequencies_NNS for_IN each_DT gene_NN will_MD be_VB tested_VBN for_IN departure_NN
          from_IN Hardy-_NNP Weinberg_NNP equilibrium_NN ._. Statistically_NNP
          significant_JJ departures_NNS could_MD indicate_VB biased_VBN sampling_VBG or_CC
          they_PRP could_MD indicate_VB that_IN the_DT study_NN population_NN is_VBZ
          experiencing_VBG detectably_RB strong_JJ natural_JJ selection_NN at_IN that_DT
          locus_JJ ._.
          The_DT null_NN hypothesis_NNS to_TO be_VB tested_VBN for_IN each_DT gene_NN is_VBZ that_IN
          the_DT genotypic_JJ frequencies_NNS in_IN patients_NNS with_IN normal_JJ and_CC
          high_JJ TCD_NNP are_VBP the_DT same_JJ ._. This_DT will_MD be_VB tested_VBN using_VBG a_DT
          chi-square_JJ test_NN of_IN association_NN of_IN TCD_NNP status_NN and_CC genotype_NN
          for_IN each_DT gene_NN ._. Heterozygotes_NNP will_MD be_VB pooled_VBN with_IN
          homozygous_JJ mutants_NNS to_TO form_VB 2_CD ×_NN 2_CD tables_NNS (_( mutant_JJ
          present_JJ /_NN absent_JJ vs_NNS ._. TCD_NNP status_NN )_) ._. Fisher_NNP 's_POS exact_JJ test_NN will_MD
          be_VB used_VBN instead_RB of_IN chi-square_JJ tests_NNS if_IN the_DT frequency_NN of_IN a_DT
          given_VBN allele_NN is_VBZ too_RB low_JJ to_TO justify_VB the_DT assumptions_NNS of_IN the_DT
          chi-square_JJ test_NN ._. Rejection_NN of_IN the_DT null_NN hypothesis_NNS of_IN no_DT
          association_NN between_IN genotype_NN and_CC TCD_NNP status_NN will_MD lead_VB to_TO
          the_DT conclusion_NN that_IN the_DT proportion_NN of_IN patients_NNS with_IN
          mutant_JJ alleles_NNS is_VBZ different_JJ in_IN patients_NNS with_IN normal_JJ and_CC
          high_JJ TCD_NNP ._. The_DT Bonferroni_NNP correction_NN for_IN multiple_JJ testing_NN
          will_MD not_RB be_VB used_VBN because_IN correcting_VBG for_IN tests_NNS at_IN 20_CD loci_NN
          would_MD produce_VB an_DT extremely_RB small_JJ critical_JJ p-value_JJ ._. In_IN the_DT
          absence_NN of_IN such_JJ a_DT correction_NN ,_, the_DT results_NNS of_IN this_DT study_NN
          will_MD need_VB to_TO be_VB considered_VBN with_IN caution_NN and_CC replication_NN
          of_IN significant_JJ findings_NNS in_IN an_DT independent_JJ sample_NN or_CC
          follow-up_JJ study_NN will_MD be_VB important_JJ ._.
          A_DT multivariate_NN approach_NN will_MD then_RB be_VB employed_VBN to_TO
          determine_VB if_IN TCD_NNP status_NN varies_VBZ with_IN combinations_NNS of_IN
          different_JJ genes_NNS ;_: i_NNP ._. e_SYM ._. to_TO determine_VB if_IN the_DT probability_NN
          that_IN a_DT patient_NN with_IN mutant_JJ alleles_NNS for_IN two_CD or_CC more_JJR genes_NNS
          is_VBZ a_DT case_NN (_( i_NNP ._. e_SYM ._. has_VBZ high_JJ TCD_NNP )_) differs_VBZ from_IN the_DT
          probability_NN that_WDT is_VBZ predicted_VBN from_IN the_DT independent_JJ
          effects_NNS of_IN those_DT genes_NNS ._. Loglinear_NNP models_NNS will_MD be_VB employed_VBN
          for_IN this_DT [_NN 19_CD ]_NN ._. Suppose_VB ,_, for_IN example_NN ,_, that_IN the_DT data_NNS
          from_IN two_CD genes_NNS are_VBP combined_VBN with_IN TCD_NNP status_NN to_TO form_VB a_DT 2_CD ×_NN
          2_CD ×_NN 2_CD table_NN ._. Rejection_NN of_IN the_DT null_NN hypothesis_NNS of_IN no_DT
          three-way_JJ association_NN in_IN the_DT table_NN would_MD lead_VB to_TO the_DT
          conclusion_NN that_IN the_DT proportion_NN with_IN high_JJ TCD_NNP depends_VBZ upon_IN
          the_DT joint_JJ effects_NNS of_IN the_DT two_CD genes_NNS rather_RB than_IN on_IN their_PRP$
          separate_JJ effects_NNS ._. The_DT cell_NN frequencies_NNS in_IN the_DT table_NN would_MD
          then_RB be_VB inspected_VBN to_TO determine_VB which_WDT combinations_NNS of_IN
          alleles_NNS accounted_VBD for_IN the_DT statistically_RB significant_JJ
          results_NNS ;_: i_NNP ._. e_SYM ._. to_TO identify_VB the_DT combinations_NNS that_WDT occur_VBP
          with_IN elevated_JJ frequency_NN in_IN patients_NNS with_IN high_JJ TCD_NNP ._. Bishop_NNP
          et_CC al_NN ._. [_NN 19_CD ]_NN provide_VB methods_NNS for_IN calculating_VBG standard_JJ
          errors_NNS for_IN the_DT cell_NN frequencies_NNS for_IN this_DT inspection_NN ._.
          Generally_RB ,_, statistical_JJ tests_NNS of_IN three-way_JJ and_CC higher_JJR
          order_NN associations_NNS are_VBP less_RBR powerful_JJ than_IN tests_NNS of_IN
          two-way_JJ associations_NNS in_IN the_DT same_JJ table_NN ._. More_RBR specific_JJ
          statements_NNS regarding_VBG power_NN are_VBP difficult_JJ without_IN explicit_JJ
          statements_NNS regarding_VBG the_DT magnitude_NN of_IN interaction_NN to_TO be_VB
          detected_VBN and_CC there_EX is_VBZ very_RB little_JJ information_NN available_JJ
          on_IN which_WDT to_TO base_VB the_DT latter_NN ._. Therefore_RB ,_, the_DT analysis_NN of_IN
          individual_JJ genes_NNS should_MD be_VB considered_VBN the_DT primary_JJ
          analysis_NN in_IN this_DT study_NN ._. Interactions_NNP involving_VBG more_JJR than_IN
          three_CD or_CC four_CD variables_NNS are_VBP generally_RB very_RB difficult_JJ to_TO
          interpret_VB ._. Therefore_RB ,_, the_DT analysis_NN will_MD be_VB limited_VBN to_TO
          tables_NNS involving_VBG no_DT more_JJR than_IN two_CD or_CC three_CD genes_NNS ._. Even_RB
          that_DT restriction_NN is_VBZ unlikely_JJ to_TO be_VB sufficient_JJ ,_, given_VBN the_DT
          large_JJ number_NN of_IN tables_NNS involving_VBG either_CC two_CD or_CC three_CD
          genes_NNS that_WDT could_MD be_VB formed_VBN from_IN the_DT data_NNS ._. Therefore_RB ,_,
          multivariate_NN modeling_NN will_MD begin_VB with_IN any_DT genes_NNS that_WDT were_VBD
          statistically_RB significantly_RB related_VBN to_TO TCD_NNP status_NN when_WRB
          the_DT data_NNS for_IN each_DT gene_NN were_VBD analyzed_VBN separately_RB ._.
        
        
          Power_NN estimates_NNS for_IN the_DT candidate_NN gene_NN study_NN
          In_IN the_DT calculations_NNS below_IN ,_, heterogyzotes_NNS are_VBP pooled_VBN
          with_IN homozygous_JJ mutants_NNS to_TO reduce_VB each_DT population_NN to_TO two_CD
          states_NNS (_( mutant_JJ present_JJ or_CC absent_JJ )_) ._. The_DT power_NN to_TO detect_VB a_DT
          difference_NN in_IN genotypic_JJ frequencies_NNS between_IN two_CD
          populations_NNS was_VBD determined_VBN by_IN Monte_NNP Carlo_NNP simulation_NN ._. The_DT
          simulations_NNS were_VBD based_VBN on_IN three_CD assumptions_NNS :_: (_( i_NNP )_) only_RB two_CD
          alleles_NNS are_VBP involved_VBN in_IN the_DT comparison_NN for_IN a_DT given_VBN gene_NN ;_:
          (_( ii_NN )_) the_DT populations_NNS are_VBP in_IN Hardy-_NNP Weinberg_NNP equilibrium_NN ;_:
          and_CC (_( iii_NN )_) genotypes_NNS will_MD be_VB obtained_VBN from_IN 230_CD cases_NNS and_CC
          400_CD controls_NNS ._. The_DT simulations_NNS proceeded_VBD as_IN follows_VBZ ._.
          1_LS ._. Specify_NNP the_DT proportion_NN of_IN homozygous_JJ mutants_NNS in_IN
          each_DT population_NN (_( p_NN 
          1_CD for_IN cases_NNS and_CC p_NN 
          2_CD for_IN controls_NNS )_) ._. The_DT proportions_NNS of_IN
          homozygous_JJ wild_JJ type_NN and_CC heterozygous_JJ patients_NNS in_IN the_DT i_NNP
          thpopulation_NN are_VBP then_RB (_( 1_CD -_: p_NN 
          i_NNP 1_CD /_NN 2_LS )_) 2_CD and_CC 2_CD p_NN 
          i_NNP 1_CD /_NN 2_CD (_( 1_CD -_: p_NN 
          i_NNP 1_CD /_NN 2_LS )_) respectively_RB ._.
          2_LS ._. Draw_NNP random_JJ samples_NNS of_IN size_NN 230_CD and_CC 400_CD from_IN the_DT
          two_CD multinomial_NN populations_NNS defined_VBN above_IN ._. Pool_NNP the_DT
          heterozygotes_NNS and_CC homozygous_JJ mutants_NNS to_TO reduce_VB each_DT
          population_NN to_TO two_CD states_NNS (_( mutant_JJ present_JJ /_NN absent_JJ )_) ._.
          3_LS ._. Compare_VB the_DT genotypic_JJ frequencies_NNS in_IN the_DT two_CD
          samples_NNS using_VBG a_DT chi-square_JJ test_NN ._.
          4_LS ._. Repeat_NN steps_NNS 2_CD -_: 3_CD 5_CD ,_, 000_CD times_NNS for_IN each_DT combination_NN
          of_IN p_NN 
          1_CD and_CC p_NN 
          2_CD ._. Estimate_NNP statistical_JJ power_NN as_IN the_DT
          percentage_NN of_IN simulations_NNS in_IN which_WDT the_DT null_NN hypothesis_NNS
          was_VBD rejected_VBN ._.
          Results_NNS are_VBP presented_VBN in_IN table_NN 2_CD ._. On_IN the_DT assumption_NN
          that_IN the_DT goal_NN of_IN the_DT study_NN is_VBZ to_TO identify_VB mutant_JJ alleles_NNS
          that_WDT occur_VBP with_IN increased_VBN frequency_NN in_IN patients_NNS with_IN high_JJ
          TCD_NNP ,_, the_DT table_NN is_VBZ limited_VBN to_TO cases_NNS in_IN which_WDT p_NN 
          1_CD >_NN p_NN 
          2_CD ._. To_TO save_VB space_NN ,_, the_DT table_NN is_VBZ
          further_JJ limited_VBN to_TO entries_NNS that_WDT just_RB span_NN the_DT range_NN of_IN
          differences_NNS ,_, p_NN 
          1_CD -_: p_NN 
          2_CD ,_, that_WDT can_MD be_VB detected_VBN with_IN 80_CD -_: 90_CD %_NN
          power_NN for_IN each_DT specified_VBN value_NN of_IN p_NN 
          1_CD ._. Based_VBN on_IN these_DT power_NN analyses_NNS we_PRP
          conclude_VBP that_IN we_PRP have_VBP good_JJ power_NN to_TO detect_VB realistic_JJ
          differences_NNS in_IN frequencies_NNS of_IN alleles_NNS that_WDT increase_NN risk_NN
          of_IN cerebrovascular_NN disease_NN and_CC stroke_NN in_IN cases_NNS as_IN
          compared_VBN to_TO controls_NNS ._.
        
        
          Design_NNP of_IN DNA_NNP pooling_VBG for_IN genomewide_NN association_NN
          screen_NN
          DNA_NNP pooling_VBG is_VBZ a_DT practical_JJ way_NN to_TO reduce_VB the_DT cost_NN of_IN
          large-scale_JJ case-control_JJ association_NN studies_NNS ,_, because_IN it_PRP
          allows_VBZ measurement_NN of_IN allele_NN frequencies_NNS in_IN groups_NNS (_( or_CC
          pools_NNS )_) of_IN individuals_NNS ,_, thereby_RB reducing_VBG the_DT number_NN of_IN PCR_NNP
          reactions_NNS and_CC genotyping_VBG assays_NNS dramatically_RB ._. Primer_NNP
          extension_NN is_VBZ the_DT technique_NN that_WDT has_VBZ been_VBN most_RBS commonly_RB
          used_VBN in_IN pooling_VBG studies_NNS to_TO genotype_NN SNPs_NNP and_CC the_DT results_NNS
          have_VBP been_VBN very_RB good_JJ [_NN 20_CD ]_NN ._. Resolution_NNP of_IN allele_NN
          frequency_NN differences_NNS between_IN cases_NNS and_CC controls_NNS in_IN
          pooling_VBG studies_NNS is_VBZ limited_VBN ,_, however_RB ,_, by_IN so_RB called_VBN
          pool-measurement_JJ and_CC pool-formation_JJ errors_NNS ._. Differential_NNP
          amplification_NN of_IN different_JJ SNPs_NNP during_IN PCR_NNP and_CC the_DT
          limited_JJ accuracy_NN of_IN the_DT detection_NN method_NN lead_NN to_TO
          pool-measurement_JJ errors_NNS ._. For_IN example_NN ,_, allele_NN frequency_NN
          estimates_NNS of_IN pools_NNS using_VBG MALDI-TOF_NNP mass_NN spectroscopy_NN have_VBP
          been_VBN reported_VBN to_TO deviate_NN from_IN real_JJ by_IN approximately_RB 3_CD %_NN [_NN
          21_CD ]_NN ._. Another_DT source_NN of_IN error_NN is_VBZ caused_VBN by_IN unequal_JJ
          amount_NN of_IN DNA_NNP being_VBG contributed_VBN by_IN individuals_NNS that_WDT make_VBP
          up_RP the_DT pool_NN (_( pool-formation_JJ errors_NNS )_) ._. In_IN principle_NN the_DT
          power_NN of_IN pooling_VBG studies_NNS can_MD be_VB improved_VBN by_IN creating_VBG
          multiple_JJ pools_NNS from_IN the_DT same_JJ individuals_NNS (_( reducing_VBG
          pool-formation_JJ errors_NNS )_) and_CC multiple_JJ measurement_NN of_IN allele_NN
          frequencies_NNS (_( reducing_VBG the_DT pool-measurement_JJ error_NN )_) ._.
          However_RB ,_, for_IN our_PRP$ study_NN we_PRP propose_VBP to_TO follow_VB the_DT
          recommendations_NNS as_RB recently_RB outlined_VBN by_IN Sham_NNP et_CC al_NN [_NN 20_CD ]_NN
          ._. They_PRP state_VBP that_IN a_DT two-stage_JJ design_NN ,_, in_IN which_WDT markers_NNS
          showing_VBG positive_JJ association_NN in_IN a_DT pooling_VBG study_NN are_VBP
          followed_VBN up_RP by_IN confirmatory_NN individual_JJ genotyping_VBG ,_, might_MD
          represent_VB the_DT best_JJS trade-off_NN between_IN the_DT cost_NN savings_NNS of_IN
          pooling_VBG and_CC the_DT full_JJ information_NN provided_VBN by_IN individual_JJ
          genotyping_VBG ._. We_PRP propose_VBP to_TO test_VB the_DT full_JJ marker_NN set_NN of_IN
          100_CD ,_, 000_CD SNPs_NNP in_IN the_DT genome_NN screen_NN using_VBG pooled_VBN assays_NNS
          with_IN a_DT relatively_RB liberal_JJ p-value_JJ (_( e_SYM ._. g_SYM ._. 0_CD ._. 01_CD -_: 0_CD ._. 001_CD )_) to_TO
          allow_VB adequate_JJ power_NN even_RB with_IN information_NN loss_NN ._. Markers_NNP
          that_DT show_NN significance_NN in_IN the_DT pooled_VBN assay_NN will_MD then_RB be_VB
          genotyped_JJ in_IN all_DT individuals_NNS of_IN the_DT original_JJ case-control_JJ
          sample_NN to_TO confirm_VB the_DT association_NN ._.
        
      
      
        Discussion_NNP
        Identifying_NNP genes_NNS for_IN polygenic_JJ ischemic_JJ stroke_NN has_VBZ been_VBN
        a_DT difficult_JJ task_NN and_CC most_RBS human_JJ studies_NNS have_VBP employed_VBN a_DT
        candidate_NN gene_NN approach_NN [_NN 5_CD ]_NN although_IN at_IN least_JJS one_CD
        genomewide_NN linkage_NN scan_VB in_IN affected_VBN sibling_VBG pairs_NNS is_VBZ on_IN the_DT
        way_NN [_NN 22_CD ]_NN ._. We_PRP propose_VBP to_TO use_VB a_DT combination_NN of_IN a_DT candidate_NN
        gene_NN association_NN study_NN and_CC genomewide_NN association_NN scan_VB in_IN
        children_NNS with_IN Hb_NNP SS_NNP at_IN high_JJ (_( 230_CD cases_NNS )_) or_CC low_JJ (_( 400_CD
        controls_NNS )_) risk_NN for_IN cerebrovascular_NN disease_NN as_IN determined_VBN by_IN
        their_PRP$ TCD_NNP velocity_NN ._.
        Association_NN studies_NNS of_IN candidate_NN genes_NNS for_IN complex_JJ
        diseases_NNS have_VBP been_VBN criticized_VBN because_IN of_IN non-replication_JJ of_IN
        results_NNS [_NN 23_CD ]_NN and_CC studies_NNS of_IN genetic_JJ risk_NN factors_NNS in_IN
        ischemic_JJ stroke_NN have_VBP been_VBN no_DT exception_NN [_NN 5_CD 22_CD ]_NN ._. Rish_NNP [_NN 24_CD
        ]_NN has_VBZ argued_VBN that_IN the_DT most_RBS likely_JJ reason_NN for_IN the_DT high_JJ
        false-positive_JJ rate_NN is_VBZ the_DT low_NN prior_RB probability_NN in_IN most_JJS
        candidate_NN gene_NN studies_NNS that_IN the_DT examined_VBN polymorphisms_NNS are_VBP
        causally_RB related_VBN to_TO the_DT disease_NN outcome_NN ._. All_DT 28_CD
        polymorphisms_NNS in_IN 20_CD candidate_NN genes_NNS that_IN we_PRP propose_VBP to_TO
        study_VB have_VBP been_VBN shown_VBN to_TO be_VB associated_VBN with_IN a_DT
        hypercoagulable_JJ state_NN or_CC have_VBP been_VBN shown_VBN to_TO be_VB involved_VBN in_IN
        pathways_NNS leading_VBG to_TO the_DT development_NN of_IN vasculopathy_NN and_CC ,_,
        therefore_RB ,_, have_VBP a_DT high_JJ probability_NN to_TO be_VB related_VBN to_TO the_DT TCD_NNP
        velocity_NN phenotype_NN ._.
        One_CD of_IN the_DT causes_NNS for_IN conflicting_JJ results_NNS in_IN candidate_NN
        gene_NN studies_NNS and_CC in_IN particular_JJ for_IN spurious_JJ associations_NNS is_VBZ
        believed_VBN to_TO be_VB population_NN stratification_NN or_CC admixture_NN [_NN 25_CD
        ]_NN ._. Population_NNP stratification_NN refers_VBZ to_TO the_DT presence_NN of_IN
        subgroups_NNS ,_, e_SYM ._. g_SYM ._. ethnic_JJ groups_NNS ,_, in_IN the_DT sample_NN and_CC can_MD
        potentially_RB cause_VB a_DT spurious_JJ association_NN between_IN the_DT locus_JJ
        and_CC trait_NN ._. A_DT spurious_JJ association_NN due_JJ to_TO population_NN
        stratification_NN can_MD only_RB occur_VB when_WRB two_CD conditions_NNS hold_VBP :_: (_( i_NNP )_)
        the_DT population_NN strata_NN differ_VB with_IN respect_NN to_TO the_DT phenotype_NN ,_,
        and_CC (_( ii_NN )_) the_DT population_NN strata_NN differ_VB in_IN allele_NN
        frequencies_NNS ._. Although_IN population_NN stratification_NN is_VBZ
        frequently_RB used_VBN as_IN an_DT explanation_NN for_IN non-replicable_JJ
        associations_NNS in_IN the_DT literature_NN ,_, there_EX are_VBP few_JJ actual_JJ
        examples_NNS to_TO support_VB this_DT assumption_NN [_NN 24_CD ]_NN and_CC experts_NNS in_IN
        the_DT field_NN now_RB agree_VBP that_IN the_DT problem_NN has_VBZ probably_RB been_VBN
        overstated_VBN [_NN 25_CD ]_NN ._. For_IN example_NN ,_, Wacholder_NNP et_CC al_NN ._. [_NN 26_CD ]_NN
        argue_VBP that_DT population_NN stratification_NN of_IN an_DT extent_NN large_JJ
        enough_RB to_TO distort_VB results_NNS is_VBZ unlikely_JJ to_TO occur_VB in_IN many_JJ
        realistic_JJ situations_NNS ._. Ardlie_NNP et_CC al_NN ._. [_NN 27_CD ]_NN evaluated_VBD 4_CD
        moderately_RB sized_VBD case-control_JJ studies_NNS for_IN the_DT presence_NN of_IN
        population_NN structure_NN and_CC concluded_VBD that_IN carefully_RB matched_VBN
        case-control_JJ samples_NNS in_IN cosmopolitan_JJ US_NNP and_CC European_JJ
        populations_NNS are_VBP unlikely_JJ to_TO contain_VB levels_NNS of_IN population_NN
        stratification_NN that_WDT would_MD result_VB in_IN significantly_RB inflated_VBN
        numbers_NNS of_IN false_JJ positive_JJ associations_NNS ._. We_PRP therefore_RB
        believe_VBP that_WDT hidden_VBN stratification_NN is_VBZ unlikely_JJ to_TO be_VB a_DT
        problem_NN in_IN our_PRP$ case-control_JJ study_NN of_IN African-_NNP American_JJ
        children_NNS with_IN sickle_NN cell_NN disease_NN at_IN high_JJ or_CC low_JJ risk_NN for_IN
        cerebrovascular_NN disease_NN based_VBN on_IN their_PRP$ TCD_NNP values_NNS ._. However_RB ,_,
        methods_NNS are_VBP being_VBG developed_VBN by_IN which_WDT unlinked_JJ genetic_JJ
        markers_NNS can_MD be_VB used_VBN to_TO detect_VB stratification_NN and_CC even_RB
        correct_JJ for_IN it_PRP when_WRB it_PRP is_VBZ present_JJ [_NN 28_CD 29_CD ]_NN ._. In_IN the_DT
        unlikely_JJ event_NN of_IN spurious_JJ association_NN results_NNS ,_, we_PRP will_MD be_VB
        able_JJ to_TO use_VB these_DT methods_NNS to_TO detect_VB and_CC adjust_VB for_IN the_DT
        effect_NN of_IN the_DT population_NN stratification_NN present_JJ ._.
        Furthermore_RB ,_, the_DT study_NN of_IN other_JJ genetic_JJ markers_NNS ,_, namely_RB the_DT
        distribution_NN of_IN β-globin_JJ haplotypes_NNS and_CC the_DT frequency_NN of_IN
        deletional_NN α-thalassemia_JJ among_IN African-_NNP American_JJ patients_NNS
        with_IN sickle_NN cell_NN disease_NN from_IN different_JJ centers_NNS in_IN the_DT
        United_NNP States_NNPS do_VBP not_RB show_VB significant_JJ differences_NNS arguing_VBG
        against_IN significant_JJ population_NN admixture_NN in_IN this_DT group_NN [_NN 4_CD
        11_CD 30_CD 31_CD ]_NN ._.
        Our_PRP$ genomewide_NN association_NN scan_VB aimed_VBN at_IN identifying_VBG
        novel_NN polymorphisms_NNS associated_VBN with_IN stroke_NN risk_NN will_MD
        necessarily_RB have_VB a_DT somewhat_RB exploratory_JJ character_NN ._. The_DT
        reason_NN is_VBZ simply_RB that_IN this_DT approach_NN has_VBZ only_RB recently_RB
        become_VB possible_JJ with_IN the_DT advent_NN of_IN high_JJ throughput_NN SNP_NNP
        genotyping_VBG and_CC we_PRP are_VBP not_RB currently_RB aware_JJ of_IN any_DT published_VBN
        studies_NNS that_WDT have_VBP used_VBN genomewide_NN association_NN for_IN
        identification_NN of_IN susceptibility_NN loci_NN of_IN complex_JJ traits_NNS ._.
        Two_CD issues_NNS are_VBP worth_JJ discussing_VBG at_IN this_DT point_NN :_: (_( i_NNP )_) the_DT
        optimization_NN of_IN selection_NN criteria_NNS for_IN the_DT case_NN and_CC control_NN
        pools_NNS and_CC (_( ii_NN )_) the_DT total_JJ number_NN of_IN SNP_NNP markers_NNS needed_VBN to_TO
        provide_VB adequate_JJ coverage_NN of_IN the_DT whole_JJ genome_NN ._.
        Our_PRP$ definition_NN of_IN cases_NNS and_CC controls_NNS in_IN this_DT study_NN is_VBZ
        based_VBN on_IN absolute_JJ cut-off_JJ values_NNS for_IN TCD_NNP velocity_NN ._. For_IN
        quantitative_JJ traits_NNS like_IN TCD_NNP velocity_NN ,_, loss_NN of_IN efficiency_NN
        in_IN a_DT pooling_VBG design_NN is_VBZ due_JJ to_TO loss_NN of_IN information_NN from_IN
        within-pool_JJ phenotypic_JJ differences_NNS ._. In_IN the_DT absence_NN of_IN
        experimental_JJ errors_NNS ,_, this_DT information_NN loss_NN can_MD be_VB minimized_VBN
        by_IN optimizing_VBG the_DT criteria_NNS for_IN selection_NN of_IN individuals_NNS
        from_IN the_DT extreme_JJ tails_NNS of_IN the_DT distribution_NN for_IN the_DT two_CD
        pools_NNS ,_, which_WDT turns_VBZ out_IN to_TO be_VB the_DT upper_JJ and_CC lower_JJR 27_CD %_NN of_IN
        this_DT distribution_NN [_NN 20_CD ]_NN ._. Interestingly_RB ,_, this_DT optimal_NN
        pooling_VBG fraction_NN is_VBZ largely_RB independent_JJ of_IN marker_NN frequency_NN
        and_CC mode_NN of_IN inheritance_NN of_IN the_DT trait_NN ._. Exploration_NNP of_IN
        alternative_JJ selection_NN criteria_NNS for_IN cases_NNS and_CC controls_NNS in_IN
        our_PRP$ genomewide_NN association_NN study_NN will_MD be_VB dependent_JJ on_IN the_DT
        combined_VBN TCD_NNP distribution_NN of_IN the_DT 1000_CD to_TO 1400_CD new_JJ patients_NNS
        that_WDT will_MD be_VB screened_VBD as_IN part_NN of_IN the_DT STOP-II_NNP study_NN and_CC the_DT
        130_CD patients_NNS (_( TCD_NNP ≥_NN 200_CD cm_NN /_NN s_VBZ )_) from_IN the_DT original_JJ STOP_NNP study_NN
        that_WDT are_VBP already_RB available_JJ ._.
        The_DT number_NN of_IN SNPs_NNP that_WDT are_VBP required_VBN for_IN whole-genome_JJ
        linkage_NN disequilibrium_NN (_( LD_NNP )_) mapping_NN has_VBZ been_VBN a_DT hotly_RB
        debated_VBN issue_NN in_IN the_DT last_JJ few_JJ years_NNS ._. Initial_JJ simulation_NN
        estimates_NNS based_VBN on_IN monotonic_JJ population_NN expansion_NN suggested_VBD
        that_IN useful_JJ LD_NNP was_VBD unlikely_JJ to_TO extend_VB beyond_IN 3_CD kb_NN ,_, implying_VBG
        a_DT number_NN of_IN 500_CD ,_, 000_CD SNPs_NNP necessary_JJ for_IN a_DT whole-genome_JJ scan_VB
        [_NN 32_CD ]_NN ._. Another_DT study_NN looking_VBG at_IN real_JJ data_NNS found_VBD that_IN LD_NNP
        extended_VBD over_IN much_RB larger_JJR distances_NNS and_CC arrived_VBD at_IN an_DT
        estimate_NN as_RB small_JJ as_IN 30_CD ,_, 000_CD SNPs_NNP ,_, or_CC 1_CD SNP_NNP per_IN 100_CD kb_NN [_NN 33_CD
        ]_NN ._. Recent_JJ evidence_NN suggests_VBZ that_IN the_DT genome_NN consists_VBZ of_IN
        blocks_NNS of_IN high_JJ LD_NNP (_( haplotype_NN blocks_NNS )_) separated_VBN by_IN
        recombination_NN hot_JJ spots_NNS [_NN 34_CD ]_NN ._. Within_IN each_DT block_NN ,_, a_DT
        limited_JJ number_NN of_IN common_JJ haplotypes_NNS (_( three_CD to_TO five_CD )_)
        typically_RB capture_VB about_IN 90_CD %_NN of_IN all_DT chromosomes_NNS ,_, which_WDT means_VBZ
        that_IN a_DT reduced_VBN number_NN of_IN SNPs_NNP would_MD be_VB needed_VBN to_TO
        characterize_VB these_DT haplotypes_NNS [_NN 35_CD ]_NN ._. Thus_RB ,_, the_DT recently_RB
        initiated_VBN construction_NN of_IN a_DT haplotype_NN map_NN of_IN the_DT human_JJ
        genome_NN may_MD facilitate_VB selection_NN of_IN SNP_NNP markers_NNS for_IN
        genomewide_NN association_NN studies_NNS like_IN ours_PRP ._. In_IN the_DT meantime_NN ,_,
        replication_NN of_IN significant_JJ associations_NNS detected_VBD in_IN the_DT
        candidate_NN gene_NN part_NN of_IN the_DT study_NN with_IN our_PRP$ genomewide_NN
        approach_NN should_MD provide_VB us_PRP with_IN practical_JJ estimates_NNS for_IN the_DT
        likely_JJ density_NN of_IN SNP_NNP markers_NNS needed_VBN for_IN successful_JJ LD_NNP
        mapping_NN ._.
        The_DT practical_JJ and_CC clinical_JJ implications_NNS of_IN potential_JJ
        findings_NNS of_IN this_DT study_NN remain_VB unclear_JJ ._. The_DT association_NN of_IN
        one_CD or_CC more_JJR polymorphisms_NNS in_IN the_DT candidate_NN genes_NNS with_IN a_DT
        high_JJ TCD_NNP (_( high_JJ risk_NN )_) phenotype_NN will_MD enable_VB the_DT
        investigators_NNS to_TO streamline_VB the_DT screening_NN and_CC follow-up_JJ
        programs_NNS towards_IN those_DT with_IN high_JJ risk_NN as_IN determined_VBN by_IN
        genetic_JJ testing_NN ._. The_DT incorporation_NN of_IN any_DT preventive_JJ or_CC
        therapeutic_JJ measures_NNS into_IN this_DT program_NN will_MD depend_VB not_RB only_RB
        on_IN the_DT findings_NNS of_IN association_NN of_IN high_JJ TCD_NNP phenotype_NN with_IN
        certain_JJ SNPs_NNP but_CC also_RB on_IN the_DT results_NNS of_IN the_DT ongoing_JJ STOP_NNP II_NNP
        study_NN ,_, which_WDT is_VBZ studying_VBG the_DT optimal_NN duration_NN of_IN
        transfusion_NN in_IN these_DT high_JJ risk_NN children_NNS ._.
        In_IN conclusion_NN ,_, we_PRP believe_VBP that_IN our_PRP$ dual_JJ approach_NN of_IN a_DT
        candidate_NN gene_NN and_CC whole-genome_JJ association_NN study_NN will_MD
        yield_VB important_JJ information_NN on_IN genetic_JJ risk_NN factors_NNS for_IN
        cerebrovascular_NN disease_NN in_IN sickle_NN cell_NN disease_NN ._. Not_RB only_RB
        will_MD this_DT generate_VB important_JJ knowledge_NN for_IN improving_VBG
        treatment_NN and_CC prevention_NN options_NNS of_IN patients_NNS with_IN Hb_NNP SS_NNP ,_,
        polymorphisms_NNS showing_VBG a_DT significant_JJ association_NN will_MD also_RB
        be_VB strong_JJ candidates_NNS for_IN stroke_NN risk_NN in_IN the_DT general_JJ
        population_NN ._. Such_JJ associations_NNS can_MD efficiently_RB be_VB confirmed_VBN
        in_IN banked_JJ DNA_NNP of_IN large_JJ cohorts_NNS of_IN stroke_NN cases_NNS and_CC controls_NNS
        [_NN 22_CD ]_NN ._.
      
      
        List_NN of_IN Abbreviations_NNP
        ACE_NNP angiotensin_NN converting_VBG enzyme_NN
        CSSCD_NNP Cooperative_NNP Study_NNP of_IN Sickle_NNP Cell_NNP Disease_NNP
        Gp_NNP platelet_NN glycoprotein_NN
        Hb_NNP SS_NNP sickle_NN cell_NN anemia_NN
        ICAM-_NNP 1_CD intercellular_NN adhesion_NN molecule_NN 1_CD
        LD_NNP linkage_NN disequilibrium_NN
        MALDI-TOF_NNP Matrix_NNP Assisted_NNP Laser_NNP Desorption_NNP /_NN Ionization_NNP
        Time-of-_NNP Flight_NNP
        MCG_NNP Medical_NNP College_NNP of_IN Georgia_NNP
        MTHFR_NNP Methylenetetrahydrofolate_NNP reductase_NN
        PAI-_NNP 1_CD plasminogen_NN activator_NN inhibitor-_NN 1_CD
        SNP_NNP single_JJ nucleotide_NN polymorphism_NN
        STOP_NNP study_NN Stroke_NNP Prevention_NNP Trial_NNP in_IN Sickle_NNP Cell_NNP Anemia_NNP
        study_NN
        TCD_NNP transcranial_NN doppler_NN
        TM_NNP thrombomodulin_NN
        TNFα_NNP tumor_NN necrosis_NNS factor_NN α_NN
        
          VCAM-_NNP 1_CD vascular_NN cell_NN adhesion_NN molecule_NN
          1_CD 
        
      
      
        Competing_VBG Interests_NNP
        None_NN declared_VBD ._.
      
      
        Author_NN 's_POS Contributions_NNP
        GTA_NNP participated_VBD in_IN primer_NN design_NN and_CC in_IN the_DT drafting_VBG of_IN
        the_DT manuscript_NN ._.
        HS_NNP participated_VBD in_IN the_DT design_NN of_IN the_DT study_NN and_CC in_IN the_DT
        drafting_VBG of_IN the_DT manuscript_NN ._.
        VCM_NNP participated_VBD in_IN the_DT design_NN of_IN the_DT study_NN and_CC by_IN
        consenting_VBG and_CC collecting_VBG patient_NN samples_NNS ._.
        BC_NNP participated_VBD in_IN the_DT design_NN of_IN the_DT study_NN and_CC in_IN its_PRP$
        coordination_NN ._.
        DB_NNP participated_VBD in_IN the_DT design_NN of_IN the_DT study_NN and_CC will_MD
        perform_VB all_DT statistical_JJ analysis_NN of_IN the_DT data_NNS ._.
        RJA_NNP participated_VBD in_IN the_DT design_NN of_IN the_DT study_NN and_CC serves_VBZ
        as_IN the_DT PI_NNP of_IN the_DT parent_JJ STOP_NNP and_CC STOP_NNP II_NNP studies_NNS ._.
        FK_NNP participated_VBD in_IN the_DT design_NN of_IN study_NN methods_NNS ._.
        AK_NNP conceived_VBD of_IN the_DT study_NN ,_, participated_VBD in_IN its_PRP$ design_NN
        and_CC coordination_NN ,_, and_CC finalized_VBD the_DT manuscript_NN ._.
      
    
  
